Perrigo Announces FDA Final Approval For Generic Version Of Nitrolingual SprayPerrigo Co. (NYSE: PRGO) announced that it has received final approval for its abbreviated new drug application for nitroglycerin lingual spray, 400 mcg/spray, the generic equivalent to Nitrolingual Pumpspray.
Perrigo Sets Records For Quarterly, Annual Sales, ProfitsThe Allegan health and beauty products maker Perrigo Co. (Nasdaq: PRGO) reported record sales and net income for the fourth fiscal quarter and fiscal year ended June 29.
Perrigo Company Announces Quarterly DividendPerrigo Co. (NYSE: PRGO) announced that its board of directors declared a quarterly dividend of 9 cents per share.
Perrigo Launching Three New ProductsThe Allegan generic drug maker will begin making two oils for dermatitis and a cancer drug.
Perrigo Acquires Irish Competitor, Will Become Irish CompanyThe Allegan generic and store-brand health products maker Perrigo Co. announced early Monday that it would acquire Dublin, Ireland-based Elan Corp. plc for $8.6 billion (5.6 billion pounds).
Perrigo Reports Record Revenue; Acquisition Charges Ding ProfitsThe generic drug and store brand health products maker Perrigo Co. (Nasdaq: PRGO) Wednesday reported record revenue of $919.8 million in the third fiscal quarer ended March 30, up from $778 million a year earlier.
Perrigo Announces Commercial Launch Of Betamethasone FoamPerrigo Co. Tuesday announced that it has begun commercial shipments of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam, consistent with the date certain launch settlement previously announced.
Perrigo Announces Launch of Authorized Generic Version of Acetadote, Plus Infant FormulasAllegan-based Perrigo Co. announced that it has made initial shipments distributing Cumberland Pharmaceuticals Inc.'s authorized generic form of Acetadote (acetylcysteine) injection, and that it had received FDA clearance to manufacture new infant formula products.
Perrigo Confirms Settlement Of Generic Acetadote Injection Patent LawsuitThe generic drug and over-the-counter health product manufacturer Perrigo Co. (Nasdaq: PRGO) announced that it has agreed to settle its Hatch-Waxman litigation relating to Acetadote (acetylcysteine) injection brought by Cumberland Pharmaceuticals Inc.
Perrigo Reports Record First Quarter Revenue, EarningsThe Allegan-based generic drug and health products manufacturer Perrigo Co. (Nasdaq: PRGO) Wednesday reported net income of $106 million or $1.12 a share in the first fiscal quarter ended Sept. 29, up from $70.5 or 75 cents a share in the same quarter a year earlier.
Perrigo Sales, Profits Both Jump 15 Percent For Fiscal YearThe generic drug and store-brand health and beauty products maker Perrigo Co. (Nasdaq: PRGO) Thursday reported net income fo $393 million or $4.18 a share in its fiscal year ended June 30, up 15 percent from $340.6 million or $3.64 a share in the prior fiscal year.